Bullous pemphigoid

3 papers study it4 more mention it1 finding

Humans2

Associations

1

DPP-4 inhibitors

upin humans1HR 1.78

1 study

DPP-4 inhibitors raise the risk of bullous pemphigoid in humans (HR 1.78, 95% CI 1.24-2.46).
“bullous pemphigoid (HR 1.78, 95% CI 1.24-2.46)”
Humanscompared with GLP-1RA in patients with type 2 diabetes3 yearsn = 118,419
Autoimmune Disease Risk With GLP-1RA, DPP-4i, and SGLT2i Treatment in Patients With Diabetes
ACR open rheumatologyJul 1, 2026

More on DPP-4 inhibitors

Trial sponsors

argenx
Company2 trialsPhase 3162 people
Regeneron
Company1 trialPhase 2/3106 people
All India Institute of Medical Sciences
1 trialPhase 462 people
All India Institute of Medical Sciences Bhubaneswar
1 trialPhase 462 people
University of Iowa
1 trialPhase 42 people
University Hospital, Montpellier
1 trialPhase 3322 people

Latest

1 paper in 12 months

ACR Open RheumatologyJul 8

Autoimmune Disease Risk With GLP-1RA, DPP-4i, and SGLT2i Treatment in Patients With Diabetes

Cohort study of 118,419 peopleSGLT2 inhibitors

DiseasesMay 27

A Closer Look at the Dermatological Profile of GLP-1 Agonists

Systematic reviewGLP-1 receptor agonists

Journal of the European Academy of Dermatology and VenereologyJul 2

Functional decline among bullous pemphigoid patients: A retrospective monocentric cohort study

Cohort study of 131 peoplePopulations

Regenerative BiomaterialsJul 28

3D bioprinting-a model for skin aging

ReviewSkin

MetabolomicsOct 1

Diverse therapeutic efficacies and more diverse mechanisms of nicotinamide

ReviewInterventions

Archives of Dermatological ResearchNov 2

Mortality and risk factors among Israeli bullous pemphigoid patients

Study in peoplePopulations

Frontiers in MedicineSep 5

The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations

ReviewPopulations